LUMIRADX LIMITED and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of March 3, 2022 6.00% Convertible Senior Subordinated Notes due 2027Indenture • March 3rd, 2022 • LumiraDx LTD • Pharmaceutical preparations • New York
INDENTURE, dated as of March 3, 2022, between LumiraDx Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”).
Registration Rights AgreementRegistration Rights Agreement • March 3rd, 2022 • LumiraDx LTD • Pharmaceutical preparations • New York
LumiraDx Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), has agreed to issue and sell to the undersigned investors (each an “Investor” and, collectively, the “Investors”) its 6.00% Convertible Senior Subordinated Notes due 2027 (other than the Affiliate Notes, the “Notes”) upon the terms set forth in each Subscription Agreement, dated March 1, 2022, by and among the Company and each Investor (the “Subscription Agreement”). The Notes are convertible, at the option of the holders, into common shares, par value $0.0000028 per common share (the “Common Shares”), of the Company pursuant to the terms of that certain Indenture, dated as of the date hereof (the “Indenture”), between the Company and U.S. Bank National Association, as Trustee (the “Trustee”). To induce the Investors to enter into a Subscription Agreement and to satisfy their respective obligations thereunder, the holders of the Notes will have the benefit of
